GlassScriptPhysician profile
Christopher O Edwards
NPI 1033479878
$16,671.07
in general payments reported to CMS, 2019-2025
18 companies · $286 in 2025
The $286 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $906 · 2020: $141 · 2021: $1,512 · 2022: $6,690 · 2023: $6,196 · 2024: $940 · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,388 · Honoraria: $2,250 · Food and Beverage: $1,756 · Education: $28.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,387.50 |
| Honoraria | $2,250.00 |
| Food and Beverage | $1,756.26 |
| Education | $28.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $7,408.43 | 2019-2025 | Ultomiris, Soliris |
| Argenx US, INC. | $5,129.50 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Amylyx Pharmaceuticals, INC. | $2,600.65 | 2023-2024 | Relyvrio |
| Edw Pharma, INC. | $606.33 | 2019-2024 | Tiglutik |
| Tanabe Pharma America, INC. | $181.69 | 2024-2025 | Radicava |
| Grifols USA, LLC | $177.63 | 2019-2023 | Gamunex-C |
| Abbvie INC. | $140.94 | 2022-2024 | Botox |
| Amgen INC. | $84.01 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $74.67 | 2019-2020 | |
| Allergan, INC. | $73.93 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $48.53 | 2024-2025 | |
| Eisai INC. | $40.22 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $24.20 | 2023 | Onpattro |
| Novartis Pharmaceuticals Corporation | $19.84 | 2020 | |
| Ucb, INC. | $17.02 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acorda Therapeutics, INC | $16.61 | 2020 | |
| Zyla Life Sciences, INC. | $15.74 | 2019 | |
| Neurocrine Biosciences, INC. | $11.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.